Covered recipient · General Payments record
HAROUTIUN HAMZOIAN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine
General Payments · PY2024
$1,244.77
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,244.77 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | $300.62 | 4 |
| UCB, Inc. | $248.71 | 3 |
| EMD Serono, Inc. | $209.55 | 2 |
| E.R. Squibb & Sons, L.L.C. | $206.00 | 2 |
| GENZYME CORPORATION | $112.00 | 1 |
| Neurelis, Inc. | $107.52 | 1 |
| Amgen Inc. | $41.11 | 2 |
| Otsuka America Pharmaceutical, Inc. | $19.26 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $1,244.77 | 16 |
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $25.62 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110514810 | CMS |
| Alexion Pharmaceuticals, Inc. | $130.00 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110516180 | CMS |
| Alexion Pharmaceuticals, Inc. | $14.96 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110507192 | CMS |
| Alexion Pharmaceuticals, Inc. | $130.04 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110508138 | CMS |
| Amgen Inc. | $24.82 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117572237 | CMS |
| Amgen Inc. | $16.29 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111593702 | CMS |
| E.R. Squibb & Sons, L.L.C. | $98.48 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101306179 | CMS |
| E.R. Squibb & Sons, L.L.C. | $107.52 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101306203 | CMS |
| EMD Serono, Inc. | $78.29 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120259450 | CMS |
| EMD Serono, Inc. | $131.26 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120279030 | CMS |
| GENZYME CORPORATION | $112.00 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139696486 | CMS |
| Neurelis, Inc. | $107.52 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145643008 | CMS |
| Otsuka America Pharmaceutical, Inc. | $19.26 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118904559 | CMS |
| UCB, Inc. | $123.72 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143112685 | CMS |
| UCB, Inc. | $34.99 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143112687 | CMS |
| UCB, Inc. | $90.00 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143112689 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.